

Anti-human FOLR1 Antibody Mirvetuximab

Catalog Number: A1040

SPECIFICATIONS

Catalog Number A1040

Product Name Anti-human FOLR1 antibody

Source Recombinant anti-human FOLR1mAb produced from HEK293 cells

Clone Mirvetuximab(VH and VL sequences are derived from Olga AB, et. al. US Patent # 2024/1032584 A1)

Species Reactivity Human
Isotype Human IgG1
Lot Number #1211
Concentration 1 mg/mL

Formulation 1xPBS, pH6.8. Sterile

Stability & Storage 1 month at 4°C; 12 months at <-20°C; Avoid repeated freeze-thaw


Purity >95%

Protein Aggregation Not obvious on SDS-PAGE


Application Flow cytometry, ELISA, cell-based assay

DATA

A. Flow cytometry: Detection of human FOLR1 expression on Human FOLR1-CHO-K1 cells (Cat. # C3038) by flow cytometry. Anti-human FOLR1 antibody Mirvetuximab(Cat. #A1040)was incubated with human FOLR1-CHO-K1 cells (Cat. # C3038), followed by staining with PE-anti-human IgG.



B. SDS-PAGE analysis of anti-human FOLR1 antibody Mirvetuximab (Cat. *A1040)



BACKGROUND

Folate receptor 1 (Folate receptor alpha, FOLR1) is a glycosyl-phosphatidylinositol (GPI)-linked membrane-bound protein, which exhibits a high affinity for folic acid and its reduced folic acid derivatives. FOLR1 mediates delivery of 5-methyltetrahydrofolate to the interior of cells. FOLR1 is involved in several cellular processes, including cell growth, survival, and signaling pathways. FOLR1 is expressed in kidney, placenta, serum, milk, and in several cell lines, while its expression has been found to be elevated in tumors of epithelial origin compared to normal tissue, including ovarian, breast, brain, lung and colorectal cancers. The tumor specificity of FOLR1 makes it a promising therapeutic target for the treatment of cancer.

References

Zheng Y and Cantley LC. J Exp Med 216, 253-266. 2019.

Scaranti M, Cojocaru E, Banerjee S, Banerji U. Nature Reviews. Clinical Oncology. 17: 349-359.2020.

Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, Murphy LM, Low PS. Oncotarget. 15:4485-4495. 2017.

Nawaz FZ, Kipreos ET. Trends EndocrinolMetab. Mar. 33:159-174. 2022.

Antony AC. Annu Rev Nutr.16:501-21. 1996.